SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-22-012615 to Scholar Rock Holding Corp (SRRK) (CIK 0001727196) (SRRK)

Scholar Rock Holding Corp (SRRK) (CIK 0001727196)
Date: Nov. 21, 2022 · CIK: 0001727196 · Accession: 0000000000-22-012615

AI Filing Summary & Sentiment

File numbers found in text: 333-268329

Date
November 21, 2022
Author
Not clearly detected
Form
UPLOAD
Company
Scholar Rock Holding Corp (SRRK) (CIK 0001727196)

Letter

United States securities and exchange commission logo November 21, 2022 Jay Backstrom Chief Executive Officer Scholar Rock Holding Corp 301 Binney Street Cambridge, MA 02142 Re:Scholar Rock Holding Corp Registration Statement on Form S-3 Filed November 14, 2022 File No. 333-268329 Dear Jay Backstrom: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jesse R. Fishman

Show Raw Text
United States securities and exchange commission logo
November 21, 2022
Jay Backstrom
Chief Executive Officer
Scholar Rock Holding Corp
301 Binney Street
Cambridge, MA 02142
Re:Scholar Rock Holding Corp
Registration Statement on Form S-3
Filed November 14, 2022
File No. 333-268329
Dear Jay Backstrom:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jesse R. Fishman